INS and cardiovascular disorder: It has been reported that treatment with canagliflozin improves adipose tissue functions; modifies levels of serum leptin, adiponectin, and interleukin 6; and may favorably affect insulin sensitivity and other risk factors for cardiovascular disease [22].